Carl Zeiss Meditec AG (CZMWY)
USD 48.09
(-1.39%)
USD 48.09
(-1.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 860.02 Million EUR | 8.49% |
| 2022 | 792.72 Million EUR | 10.32% |
| 2021 | 718.58 Million EUR | 27.7% |
| 2020 | 562.72 Million EUR | -7.01% |
| 2019 | 605.17 Million EUR | 74.19% |
| 2018 | 347.41 Million EUR | -8.9% |
| 2017 | 381.37 Million EUR | -3.83% |
| 2016 | 396.56 Million EUR | 16.01% |
| 2015 | 341.84 Million EUR | 19.99% |
| 2014 | 284.88 Million EUR | 15.93% |
| 2013 | 245.73 Million EUR | -7.99% |
| 2012 | 267.07 Million EUR | 14.42% |
| 2011 | 233.42 Million EUR | -3.63% |
| 2010 | 242.22 Million EUR | 12.87% |
| 2009 | 214.59 Million EUR | -0.23% |
| 2008 | 215.09 Million EUR | 0.02% |
| 2007 | 215.06 Million EUR | 30.85% |
| 2006 | 164.35 Million EUR | 2.36% |
| 2005 | 160.55 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 812.91 Million EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2024 Q3 | -2.1 Billion EUR | -359.22% |
| 2023 Q4 | 860.02 Million EUR | 0.0% |
| 2023 FY | 860.02 Million EUR | 8.49% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q2 | 754.05 Million EUR | 0.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 792.72 Million EUR | 0.0% |
| 2022 FY | 792.72 Million EUR | 10.32% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 769.91 Million EUR | 0.0% |
| 2021 Q4 | 718.58 Million EUR | 0.0% |
| 2021 FY | 718.58 Million EUR | 27.7% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 654.44 Million EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 FY | 562.72 Million EUR | -7.01% |
| 2020 Q4 | 562.72 Million EUR | 0.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q2 | 601.11 Million EUR | 0.0% |
| 2019 Q2 | 520.06 Million EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 Q4 | 605.17 Million EUR | 0.0% |
| 2019 FY | 605.17 Million EUR | 74.19% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 FY | 347.41 Million EUR | -8.9% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q4 | 347.41 Million EUR | 0.0% |
| 2018 Q2 | 321.38 Million EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q2 | 371.75 Million EUR | 0.0% |
| 2017 FY | 381.37 Million EUR | -3.83% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 Q4 | 381.37 Million EUR | 0.0% |
| 2016 FY | 396.56 Million EUR | 16.01% |
| 2016 Q4 | 396.56 Million EUR | -1.58% |
| 2016 Q3 | 402.92 Million EUR | 16.32% |
| 2016 Q2 | 346.4 Million EUR | 5.68% |
| 2016 Q1 | 327.78 Million EUR | -4.11% |
| 2015 Q1 | 298.61 Million EUR | 4.82% |
| 2015 FY | 341.84 Million EUR | 19.99% |
| 2015 Q2 | 365.87 Million EUR | 22.52% |
| 2015 Q4 | 341.84 Million EUR | 6.57% |
| 2015 Q3 | 320.77 Million EUR | -12.33% |
| 2014 FY | 284.88 Million EUR | 15.93% |
| 2014 Q4 | 284.88 Million EUR | 5.04% |
| 2014 Q2 | 276.86 Million EUR | 17.97% |
| 2014 Q1 | 234.7 Million EUR | -4.49% |
| 2014 Q3 | 271.21 Million EUR | -2.04% |
| 2013 Q1 | 241.61 Million EUR | -9.54% |
| 2013 FY | 245.73 Million EUR | -7.99% |
| 2013 Q3 | 224.78 Million EUR | -11.59% |
| 2013 Q2 | 254.26 Million EUR | 5.24% |
| 2013 Q4 | 245.73 Million EUR | 9.32% |
| 2012 FY | 267.07 Million EUR | 14.42% |
| 2012 Q1 | 238.74 Million EUR | 2.28% |
| 2012 Q4 | 267.07 Million EUR | 4.85% |
| 2012 Q3 | 254.72 Million EUR | 2.24% |
| 2012 Q2 | 249.14 Million EUR | 4.36% |
| 2011 Q4 | 233.42 Million EUR | 1.46% |
| 2011 Q1 | 236.49 Million EUR | -2.36% |
| 2011 Q2 | 244.32 Million EUR | 3.31% |
| 2011 Q3 | 230.05 Million EUR | -5.84% |
| 2011 FY | 233.42 Million EUR | -3.63% |
| 2010 Q4 | 242.22 Million EUR | -4.57% |
| 2010 FY | 242.22 Million EUR | 12.87% |
| 2010 Q3 | 253.83 Million EUR | 9.07% |
| 2010 Q2 | 232.72 Million EUR | 16.3% |
| 2010 Q1 | 200.1 Million EUR | -6.75% |
| 2009 Q4 | 214.59 Million EUR | 0.0% |
| 2009 FY | 214.59 Million EUR | -0.23% |
| 2008 FY | 215.09 Million EUR | 0.02% |
| 2007 FY | 215.06 Million EUR | 30.85% |
| 2006 FY | 164.35 Million EUR | 2.36% |
| 2005 FY | 160.55 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -36499.068% |
| Ansell Limited | 1.32 Billion USD | 35.332% |
| Ansell Limited | 1.33 Billion USD | 35.453% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | -580.732% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -91083.899% |
| Psykey, Inc. | 2.47 Million USD | -34662.102% |
| ConvaTec Group Plc | 2.01 Billion USD | 57.386% |
| ConvaTec Group Plc | 2.02 Billion USD | 57.446% |
| Encision Inc. | 1.98 Million USD | -43248.532% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | -28185.708% |
| Innovative MedTech Inc. | 6.13 Million USD | -13918.631% |
| LifePoint, Inc. | 2.45 Million USD | -34943.267% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | -8347.314% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | -25194.735% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 3.04 Million USD | -28187.159% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -110680.481% |
| SmileDirectClub, Inc. | 982.26 Million USD | 12.445% |
| Sector 10, Inc. | 9.84 Million USD | -8635.232% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | 36.563% |
| SheerVision, Inc. | 1.43 Million USD | -59982.381% |
| United Health Products, Inc. | 1.99 Million USD | -42925.381% |
| Vasamed, Inc. | 1 Million USD | -85448.692% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | -22530.434% |
| Yubo International Biotech Limited | 2.91 Million USD | -29414.188% |